US-based digital pathology solutions provider Gestalt has teamed up with healthcare technology company Paige to integrate the latter’s advanced AI applications into its PathFlow solution.
The collaboration aims to improve the delivery of integrated workflows, optimise the pathologist’s experience, and ensure patient accuracy and safety.
Gestalt’s PathFlow is designed with robust capabilities in primary diagnosis, education, resident training, and research workflows.
By incorporating Paige’s advanced algorithms, the PathFlow solution will now offer an even broader range of tools to support pathologists in delivering precise and efficient diagnoses.
All of Paige’s AI applications will be made available in PathFlow, enabling both current and new users to access AI-powered diagnostic capabilities.
The integration supports more efficient case reviews, accelerates diagnostic timelines, and promotes a comprehensive approach to cancer detection.
Gestalt COO and chief strategy officer Lisa-Jean Clifford said: “By partnering with Paige to include their AI applications in PathFlow, we are reinforcing our commitment to providing pathologists with the best tools available.
“This partnership underscores our dedication to enhancing the pathologist’s experience and ensuring the highest standards of patient care.”
According to Gestalt, the partnership would enhance diagnostic confidence, streamline workflows, and provide comprehensive support.
The integration of Paige’s AI applications with Gestalt’s PathFlow platform will provide easy access to Paige AI solutions for any Gestalt user.
It will provide pathologists with advanced tools to improve diagnostic confidence and patient outcomes while reducing the time and effort required to reach diagnoses.
PathFlow’s expanded algorithm library is anticipated to address a wide range of use cases, helping both current and future customers.
Paige diagnostics general manager Peter Hamilton said: “Leveraging Paige’s AI-powered applications, PathFlow users can experience an enhanced workflow that supports efficient case review, accelerates time to diagnosis, and allows for a more comprehensive approach to cancer detection.”
